Trial report in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Helen X ChenCancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
Robert J GrayDana Farber Cancer Institute-ECOG-ACRIN Biostatistical Center, Boston, MA.ORCID 0000-0002-5724-4917
Lisa M McShaneBiometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0001-8195-3206
Larry V RubinsteinBiometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
David PattonCenter for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, MD.ORCID 0000-0003-3855-0166
P Mickey WilliamsFrederick National Laboratory for Cancer Research, Frederick, MD.
Stanley R HamiltonCity of Hope National Medical Center and Comprehensive Cancer Center, Duarte, CA.ORCID 0000-0002-8331-1052
James V TricoliDivision of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
Barbara A ConleyCancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-1445-1684
Carlos L ArteagaUniversity of Texas Southwestern Medical Center, Dallas, TX.
Lyndsay N HarrisCancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-9774-6719
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
Statistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO · 2014 to 2026
$111.2M
Columbus NCORP RFA-CA-18-016UG1CA189954 · NCI · COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG · PI Aruna Gowda, Malolan S Rajagopalan · 2014 to 2026
$9.8M
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer CareUG1CA233180 · NCI · DANA-FARBER CANCER INST · PI Harold John Burstein · 2019 to 2026
$8.6M
UT Southwestern NCI National Clinical Trials Network (NCTN) LAPS - Supplemental Funds YR4UG1CA233302 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI David Eric Gerber · 2019 to 2026
$6.4M
Medical College of Wisconsin Lead Academic Participating Site RenewalUG1CA233198 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI William H Bradley, Elizabeth M Gore · 2019 to 2026
$5.0M
NCTN LAPS at Johns HopkinsUG1CA233196 · NCI · JOHNS HOPKINS UNIVERSITY · PI DEBORAH K ARMSTRONG, Julie Renee Brahmer · 2019 to 2026
$4.6M
The Duke University - Duke Cancer Institute National Clinical Trials Network LAPS (UG1) Support GrantUG1CA233253 · NCI · DUKE UNIVERSITY · PI John H Strickler, Alexandra Thomas · 2019 to 2026
purposeSubprotocol H of the NCI-MATCH trial demonstrated the efficacy of dabrafenib + trametinib in a cohort of patients with
methodsPatients with
resultsThe expansion cohort enrolled from October 2020 to January 2023. In total, 36 patients were included in the primary efficacy analysis for the combined cohort, including six patients from the expansion cohort and 30 patients from the original cohort, representing 17 different tumor histologies. Fifty-six percent of patients were female, with a median age of 60. The ORR was 36.1% (13 of 36 [90% CI, 22.9 to 51.2]). The median PFS was 11.4 months, and the median OS was 28.6 months. The 6-month PFS was 67.6% (90% CI, 54.5 to 80.8). In the six molecularly confirmed cases in the expansion cohort, there were two responses, including one complete response in a patient with a pilocytic astrocytoma; an additional two patients without molecular confirmation also had PRs. Three patients (two from the original cohort and one from the expansion cohort) remain on therapy. The safety profile was consistent with previous reports with dabrafenib and trametinib.
conclusionThis study confirms the clinical benefit of dabrafenib + trametinib in
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With · full record | OpenQuestion